Boston Scientific Corp. (BSX) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration...
Boston Scientific Corp. (BSX) currently trades at a P/E ratio of 19.69 (historical range: 17.88–87.41, median: 68.70), placing it at the 7th percentile — cheap relative to its history, P/S ratio of 3.41 (range: 3.09–10.36, 7th percentile — cheap relative to its history), EV/EBITDA of 72.46 (range: 28.65–184.41, 44th percentile).
Over the historical period (2024-08-30 to 2026-08-28), Boston Scientific Corp.'s P/E ratio has contracted by 39% over the observed period (from an average of 73.2 to 44.3).
Boston Scientific Corp. appears significantly undervalued relative to its historical range, trading at depressed multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 19.69 | 17.88 | 68.70 | 87.41 | 7th | cheap relative to its history |
| P/S Ratio | 3.41 | 3.09 | 8.38 | 10.36 | 7th | cheap relative to its history |
| EV/EBITDA | 72.46 | 28.65 | 79.32 | 184.41 | 44th | near its historical average |
| FCF Yield | 0.00 | 0.00 | 0.01 | 0.04 | 24th | above its historical average |